Evelo Biosciences Inc has a consensus price target of $6.25 based on the ratings of 3 analysts. The high is $10 issued by Morgan Stanley on July 26, 2023. The low is $2.5 issued by Chardan Capital on November 16, 2022. The 3 most-recent analyst ratings were released by Morgan Stanley, Morgan Stanley, and Chardan Capital on July 26, 2023, February 15, 2023, and November 16, 2022, respectively. With an average price target of $4.83 between Morgan Stanley, Morgan Stanley, and Chardan Capital, there's an implied 966566.67% upside for Evelo Biosciences Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Evelo Biosciences (OTCEM:EVLO) was reported by TD Cowen on October 18, 2023. The analyst firm set a price target for $0.00 expecting EVLO to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
The latest analyst rating for Evelo Biosciences (OTCEM:EVLO) was provided by TD Cowen, and Evelo Biosciences downgraded their market perform rating.
There is no last upgrade for Evelo Biosciences
The last downgrade for Evelo Biosciences Inc happened on October 18, 2023 when TD Cowen changed their price target from N/A to N/A for Evelo Biosciences Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evelo Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evelo Biosciences was filed on October 18, 2023 so you should expect the next rating to be made available sometime around October 18, 2024.
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a downgraded with a price target of $0.00 to $0.00. The current price Evelo Biosciences (EVLO) is trading at is $0.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.